Sebastian Chakrit BhakdiPrapat SuriyapholPonpan ThaicharoenSebastian Tobias Karl GroteChulaluk KomoltriBansithi ChaiyaprasithiKomgrid CharnkaewMahidol UniversityFaculty of Medicine, Siriraj Hospital, Mahidol UniversityX-ZELL2020-01-272020-01-272019-08-01Cancers. Vol.11, No.8 (2019)207266942-s2.0-85070599612https://repository.li.mahidol.ac.th/handle/20.500.14594/50114© 2019 by the authors. Licensee MDPI, Basel, Switzerland. Even though more than 350,000 men die from prostate cancer every year, broad-based screening for the disease remains a controversial topic. Guidelines demand that the only commonly accepted screening tool, prostate-specific antigen (PSA) testing, must be followed by prostate biopsy if results are elevated. Due to the procedure’s low positive predictive value (PPV), however, over 80% of biopsies are performed on healthy men or men with clinically insignificant cancer—prompting calls for new ways of vetting equivocal PSA readings prior to the procedure. Responding to the challenge, the present study investigated the diagnostic potential of tumour-associated circulating endothelial cells (tCECs), which have previously been described as a novel, blood-based biomarker for clinically significant cancers. Specifically, the objective was to determine the diagnostic accuracy of a tCEC-based blood test to detect clinically significant prostate cancer (defined as Gleason score ≥ 3 + 4) in high-risk patients. Performed in a blinded, prospective, single-centre set-up, it compared a novel tCEC index test with transrectal ultrasound-guided biopsy biopsy as a reference on a total of 170 patients and found that a tCEC add-on test will almost double the PPV of a standalone PSA test (32% vs. 17%; p = 0.0012), while retaining a negative predictive value above 90%.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.3390/cancers11081064